Suppr超能文献

用于尿路感染的磺胺类药物-甲氧苄啶联合制剂的研发。第3部分:磺胺嘧啶和磺胺甲恶唑与甲氧苄啶联用的药代动力学特征。

Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim.

作者信息

Ortengren B, Magni L, Bergan T

出版信息

Infection. 1979;7 Suppl 4:S371-81. doi: 10.1007/BF01639016.

Abstract

Plasma levels and renal excretion of sulphonamide and trimethoprim following oral administration of co-trimazine (140 mg sulphadiazine + 90 mg trimethoprim) and co-trimoxazole (800 mg sulphamethoxazole + 180 mg trimethoprim) were monitored in healthy volunteers after a single dose and in the steady state after 12-hourly dosage. The plasma levels of free, non-protein bound components after co-trimazine were approximately half those after co-trimoxazole and thus correlated with the doses given. Urine recovery of trimethoprim was better after co-trimazine (70%) than after co-trimoxazole (58%). Sixty-six percent of the sulphadiazine was recovered as unchanged, active sulphonamide in the urine compared with only 13% of the sulphamethoxazole. Consequently, the sulphonamide levels of sulphadiazine were 2.5 times those of sulphamethoxazole. With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours. The distribution volume of sulphadiazine was closer to that of trimethoprim than was that of sulphamethoxazole. On the basis of these characteristics, it has been concluded that sulphadiazine is more suitable for a fixed combination tablet with trimethoprim than sulphamethoxazole, particularly for the treatment of urinary tract infections. Some renal tubular reabsorption occurs with both unchanged sulphonamides but is more pronounced with sulphamethoxazole. The solubilities of the sulphonamides and their acetylated metabolites at acid urinary pH indicate that therapy with co-trimazine is at least as safe as with co-trimoxazole. With the former drug, the result of scrutiny for crystals after dosage until the steady state was negative, whereas crystals of acetylated sulphamethoxazole were detected and verified chemically in two of eight subjects.

摘要

在健康志愿者单次给药后以及12小时给药一次达到稳态后,监测口服复方磺胺嘧啶(140毫克磺胺嘧啶 + 90毫克甲氧苄啶)和复方新诺明(800毫克磺胺甲恶唑 + 180毫克甲氧苄啶)后磺胺类药物和甲氧苄啶的血浆水平及肾排泄情况。复方磺胺嘧啶后游离的、非蛋白结合成分的血浆水平约为复方新诺明后的一半,因此与给药剂量相关。复方磺胺嘧啶后甲氧苄啶的尿回收率(70%)高于复方新诺明(58%)。66%的磺胺嘧啶以未改变的活性磺胺形式在尿液中回收,而磺胺甲恶唑仅为13%。因此,磺胺嘧啶的磺胺类药物水平是磺胺甲恶唑的2.5倍。关于首剂后的血浆半衰期,磺胺嘧啶的8.0小时比磺胺甲恶唑的7.7小时更接近甲氧苄啶,复方磺胺嘧啶后甲氧苄啶的半衰期为8.8小时,复方新诺明后为9.6小时。磺胺嘧啶的分布容积比磺胺甲恶唑更接近甲氧苄啶。基于这些特性,得出结论:与磺胺甲恶唑相比,磺胺嘧啶更适合与甲氧苄啶制成固定复方片剂,尤其适用于治疗尿路感染。两种未改变的磺胺类药物均有一些肾小管重吸收,但磺胺甲恶唑更明显。磺胺类药物及其乙酰化代谢产物在酸性尿pH值下的溶解度表明,复方磺胺嘧啶治疗至少与复方新诺明一样安全。使用前一种药物时,直到稳态给药后晶体检查结果为阴性,而在八名受试者中的两名中检测到并经化学验证有乙酰化磺胺甲恶唑晶体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验